{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:53:16Z","timestamp":1760143996454,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>There is an ongoing need for biomarkers that could reliably predict the outcome of BC and that could guide the management of this disease. In this setting, we aimed to explore the prognostic value of the transcription factor P63 in patients with muscle-invasive bladder cancer (MIBC) having undergone radical cystectomy. The correlation between P63 expression and clinicopathological features (tumor stage, nodes involvement, patterns of muscularis propria invasion, papillary architecture, anaplasia, concomitant carcinoma in situ, lymphovascular invasion, perineural invasion, necrosis) and molecular subtyping (basal and luminal type tumors) was tested in 65 radical cystectomy specimens and matched with cancer-specific survival (CSS) and overall survival (OS). P63-negative tumors displayed significantly higher rates of pattern 2 of muscularis propria invasion (50% vs. 14%, p = 0.002) and variant histology (45% vs. 19%, p = 0.022) compared to P63-positive ones. According to the combined expression of CK5\/6 and CK20 (Algorithm #1), P63-positive and P63-negative tumors were mostly basal-like and double-negative, respectively (p = 0.004). Using Algorithm #2, based on the combined expression of CK5\/6 and GATA3, the vast majority of tumors were luminal overall and in each group (p = 0.003). There was no significant difference in CSS and OS between P63-positive and P63-negative tumors, but the former featured a trend towards longer OS. Though associated with pathological features harboring negative prognostic potential, P63 status as such failed to predict CSS and OS. That said, it may contribute to better molecular subtyping of MIBC.<\/jats:p>","DOI":"10.3390\/cimb46030155","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T05:43:30Z","timestamp":1710395010000},"page":"2456-2467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of P63 Expression in Muscle-Invasive Bladder Cancer and Association with Molecular Subtypes\u2014Preliminary Report"],"prefix":"10.3390","volume":"46","author":[{"given":"Francesca","family":"Sanguedolce","sequence":"first","affiliation":[{"name":"Pathology Unit, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo Giovanni","family":"Falagario","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-9933","authenticated-orcid":false,"given":"Magda","family":"Zanelli","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2299-5160","authenticated-orcid":false,"given":"Andrea","family":"Palicelli","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9841-7856","authenticated-orcid":false,"given":"Maurizio","family":"Zizzo","sequence":"additional","affiliation":[{"name":"Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Ascani","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Tortorella","sequence":"additional","affiliation":[{"name":"Pathology Unit, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7291-0316","authenticated-orcid":false,"given":"Gian Maria","family":"Busetto","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-7040","authenticated-orcid":false,"given":"Angelo","family":"Cormio","sequence":"additional","affiliation":[{"name":"Urology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universit\u00e0 Politecnica Delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cormio","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"},{"name":"Department of Urology, Bonomo Teaching Hospital, 76123 Andria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"unstructured":"(2023, January 31). Available online: https:\/\/gco.iarc.fr\/today\/.","key":"ref_1"},{"unstructured":"Babjuk, M., Burger, M., Comp\u00e9rat, E., Gontero, P., Liedberg, F., Masson-Lecomte, A., Mostafid, A.H., Palou, J., Van Rhijn, B.W.G., and Roupret, M. (2022). EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS), EAU.","key":"ref_2"},{"unstructured":"Witjes, J.A., Bruins, H.M., Carri\u00f3n, A., Cathomas, R., Comp\u00e9rat, E.M., Efstathiou, J.A., Kietkau, R., Gakis, G., Van der Heijden, A.G., and Lorch, A. (2022). EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer, EAU.","key":"ref_3"},{"key":"ref_4","first-page":"43","article-title":"Non-muscle-invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative Therapies","volume":"22","author":"Matulewicz","year":"2020","journal-title":"Rev. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/10408363.2015.1033610","article-title":"Molecular markers in bladder cancer: Novel research frontiers","volume":"52","author":"Sanguedolce","year":"2015","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"doi-asserted-by":"crossref","unstructured":"Sanguedolce, F., Zanelli, M., Palicelli, A., Ascani, S., Zizzo, M., Cocco, G., Bj\u00f6rnebo, L., Lantz, A., Landriscina, M., and Conteduca, V. (2022). Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation. Int. J. Mol. Sci., 23.","key":"ref_8","DOI":"10.3390\/ijms23147844"},{"doi-asserted-by":"crossref","unstructured":"Sanguedolce, F., Zanelli, M., Palicelli, A., Ascani, S., Zizzo, M., Cocco, G., Bj\u00f6rnebo, L., Lantz, A., Landriscina, M., and Conteduca, V. (2022). Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression. Int. J. Mol. Sci., 23.","key":"ref_9","DOI":"10.3390\/ijms23147819"},{"doi-asserted-by":"crossref","unstructured":"Woodstock, D.L., Sammons, M.A., and Fischer, M. (2021). p63 and p53: Collaborative Partners or Dueling Rivals?. Front. Cell Dev. Biol., 9.","key":"ref_10","DOI":"10.3389\/fcell.2021.701986"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/path.5656","article-title":"The foggy world(s) of p63 isoform regulation in normal cells and cancer","volume":"254","author":"Hrabal","year":"2021","journal-title":"J. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00428-021-03145-y","article-title":"Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion","volume":"479","author":"Haghayeghi","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25433","DOI":"10.18632\/oncotarget.15989","article-title":"Human epidermal growth factor receptor 2 expression is more important than bacillus calmette guerin treatment in predicting the outcome of T1G3 bladder cancer","volume":"8","author":"Cormio","year":"2017","journal-title":"Oncotarget"},{"doi-asserted-by":"crossref","unstructured":"Kim, B., Jang, I., Kim, K., Jung, M., Lee, C., Park, J.H., Kim, Y.A., and Moon, K.C. (2021). Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma. Int. J. Mol. Sci., 22.","key":"ref_15","DOI":"10.3390\/ijms22020628"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of Luminal and Basal Phenotypes in Bladder Cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci. Rep."},{"doi-asserted-by":"crossref","unstructured":"Zhou, H., Guo, C.C., and Ro, J.Y. (2021). Urinary Bladder Pathology, Springer.","key":"ref_17","DOI":"10.1007\/978-3-030-71509-0"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/1066896918814198","article-title":"Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review","volume":"27","author":"Sanguedolce","year":"2019","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00428-020-02951-0","article-title":"A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases","volume":"478","author":"Bontoux","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41379-018-0096-5","article-title":"Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases","volume":"31","author":"Eriksson","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/BLC-180176","article-title":"Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays","volume":"4","author":"Jakobsson","year":"2018","journal-title":"Bladder Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00428-005-0092-2","article-title":"Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases","volume":"448","author":"Camparo","year":"2006","journal-title":"Virchows Arch."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/15321819.2020.1844752","article-title":"Correlation between immunohistochemical expression of Ki-67and P63 and aggressiveness of urinary bladder urothelial carcinoma","volume":"42","author":"Abdallah","year":"2021","journal-title":"J. Immunoass. Immunochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.urology.2007.04.030","article-title":"p63 gene expression study and early bladder carcinogenesis","volume":"70","author":"Ferlicot","year":"2007","journal-title":"Urology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.14740\/wjon1234","article-title":"Prognostic Role of Epithelial-Mesenchymal Transition Markers \u201cE-Cadherin, \u03b2-Catenin, ZEB1, ZEB2 and p63\u201d in Bladder Carcinoma","volume":"10","author":"Moussa","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.18632\/oncotarget.13797","article-title":"\u0394Np63\u03b1 and microRNAs: Leveraging the epithelial-mesenchymal transition","volume":"8","author":"Stacy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9566055","DOI":"10.1155\/2022\/9566055","article-title":"The DeltaN p63 Promotes EMT and Metastasis in Bladder Cancer by the PTEN\/AKT Signalling Pathway","volume":"2022","author":"Tian","year":"2022","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"ref_28","first-page":"5501","article-title":"Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder","volume":"9","author":"Koga","year":"2003","journal-title":"Clin Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.humpath.2014.02.024","article-title":"Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder","volume":"45","author":"Paner","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer\u2014An international collaborative multistakeholder effort: Under the auspices of the EAU-ESMO Guidelines Committees","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.juro.2012.11.120","article-title":"Prognostic interest in discriminating muscularis mucosa invasion (T1a vs. T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review","volume":"189","author":"Seisen","year":"2013","journal-title":"J. Urol."},{"doi-asserted-by":"crossref","unstructured":"Choi, W., Shah, J.B., Tran, M., Svatek, R., Marquis, L., Lee, I.L., Yu, D., Adam, L., Wen, S., and Shen, Y. (2012). p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS ONE, 7.","key":"ref_32","DOI":"10.1371\/journal.pone.0030206"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11255-015-1197-4","article-title":"Prognostic value of Ki67 and p63 expressions in bladder cancer patients who underwent radical cystectomy","volume":"48","author":"Wang","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3892\/mco.2022.2535","article-title":"Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer","volume":"16","author":"Burgess","year":"2022","journal-title":"Mol. Clin. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Steurer, S., Riemann, C., B\u00fcscheck, F., Luebke, A.M., Kluth, M., Hube-Magg, C., Hinsch, A., H\u00f6flmayer, D., Weidemann, S., and Fraune, C. (2021). p63 expression in human tumors and normal tissues: A tissue microarray study on 10,200 tumors. Biomark. Res., 9.","key":"ref_35","DOI":"10.1186\/s40364-021-00260-5"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41374-018-0057-0","article-title":"Principles and approaches for reproducible scoring of tissue stains in research","volume":"98","author":"Meyerholz","year":"2018","journal-title":"Lab. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Lauss","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/his.13958","article-title":"Distinct Genetic Alterations and Luminal Molecular Subtype in Nested Variant of Urothelial Carcinoma","volume":"75","author":"Weyerer","year":"2019","journal-title":"Histopathology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"152413","DOI":"10.1016\/j.prp.2019.04.005","article-title":"Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review","volume":"215","author":"Sanguedolce","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4161\/cbt.19590","article-title":"p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells","volume":"13","author":"Marquis","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4161\/cc.4.10.2066","article-title":"\u0394Np63\u03b1 levels correlate with clinical tumor response to cisplatin","volume":"4","author":"Zangen","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00280-007-0551-3","article-title":"Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: Correlation with p63 expression","volume":"61","author":"Rocca","year":"2008","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/3\/155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:13:16Z","timestamp":1760105596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/3\/155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cimb46030155"],"URL":"https:\/\/doi.org\/10.3390\/cimb46030155","relation":{},"ISSN":["1467-3045"],"issn-type":[{"type":"electronic","value":"1467-3045"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}